We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNAi Used to Treat ALS

By Biotechdaily staff writers
Posted on 21 Mar 2005
Scientists have used RNA interference (RNAi) in transgenic mice to silence a mutated gene that causes inherited cases of amytrophic lateral sclerosis (ALS), substantially delaying both the onset and the progression rate of the disease and producing significant neuromuscular improvements. More...
The results were published in the online March 13, 2005, edition of Nature Medicine.

The scientists, from the Ecole Polytechnique Federale de Lausanne (EPFL, Switzerland; www.epfl.ch), were also able to simultaneously deliver a normal version of the gene to motor neuron cells using a single delivery mechanism. To trigger RNAi and silence a gene, short bits of double-stranded RNA are introduced into the cell, where they bind with matching sections of messenger RNA. The cell identifies the resulting messenger RNA strand as faulty and chops it up. As a result, the genetic blueprint is not delivered and the protein never gets made.

"This is the first proof of principle in the human form of a disease of the nervous system in which you can silence the gene and at the same time produce another normal form of the protein,” remarked Patrick Aebischer, EPFL president and co-author of the study.

The SOD1 mutations are "toxic gain-of-function mutations,” meaning that the protein expressed by the mutated gene has, in addition to all its normal cellular functions, some additional function that makes it toxic to the cell. "Any mutation to the SOD1 gene is fatal to motor neuron cells,” noted Dr. Aebischer. Recent research also indicates that mutant SOD1 gene expression in neighboring glial cells is also implicated in motor neuron death.

Because the normal form of the SOD1 protein may be necessary for the survival or function of adult human motor neurons, the researchers designed a gene replacement technology that allows the knock-down of all mutant SOD1 forms while permitting the expression of a normal type SOD1 protein that is resistant to RNAi-based silencing. Both these effects were expressed long-term via delivery by a single lentiviral vector.

"I would not be surprised to see, in the next ten years, this technology used for treating diseases of the nervous system, particularly diseases that involve toxic gain-of-function, such as the inherited forms of Parkinson's disease or Huntington's disease,” noted Dr. Aebischer.



Related Links:
Ecole Polytechnique

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Repetitive Pipette
VWR® Stepper Pro
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.